157 related articles for article (PubMed ID: 37688769)
21. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
[TBL] [Abstract][Full Text] [Related]
22. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Murakami Y; Kubo S; Tamori A; Itami S; Kawamura E; Iwaisako K; Ikeda K; Kawada N; Ochiya T; Taguchi YH
Sci Rep; 2015 Nov; 5():16294. PubMed ID: 26538415
[TBL] [Abstract][Full Text] [Related]
24. Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids.
Uranbileg B; Kurano M; Kano K; Sakai E; Arita J; Hasegawa K; Nishikawa T; Ishihara S; Yamashita H; Seto Y; Ikeda H; Aoki J; Yatomi Y
Clin Transl Med; 2022 Sep; 12(9):e1056. PubMed ID: 36125914
[TBL] [Abstract][Full Text] [Related]
25. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus.
Yeh TS; Wang F; Chen TC; Yeh CN; Yu MC; Jan YY; Chen MF
Ann Surg; 2014 Feb; 259(2):346-54. PubMed ID: 24135722
[TBL] [Abstract][Full Text] [Related]
26. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.
Ross RA
Trends Pharmacol Sci; 2011 May; 32(5):265-9. PubMed ID: 21367464
[TBL] [Abstract][Full Text] [Related]
27. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation.
Maganty K; Levi D; Moon J; Bejarano PA; Arosemena L; Tzakis A; Martin P
Dig Dis Sci; 2010 Dec; 55(12):3597-601. PubMed ID: 20848202
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
29. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.
Wan S; Zhao E; Weissinger D; Krantz BA; Werba G; Freeman D; Khanna LG; Siolas D; Oberstein PE; Chattopadhyay PK; Simeone DM; Welling TH
Front Immunol; 2023; 14():1067352. PubMed ID: 36798126
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study.
Chen PD; Chen LJ; Chang YJ; Chang YJ
Oncologist; 2021 Oct; 26(10):e1774-e1785. PubMed ID: 34213048
[TBL] [Abstract][Full Text] [Related]
31. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
32. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG
J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072
[TBL] [Abstract][Full Text] [Related]
33. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
34. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
[TBL] [Abstract][Full Text] [Related]
35. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
36. Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma.
Pan L; Fang J; Chen MY; Zhai ST; Zhang B; Jiang ZY; Juengpanich S; Wang YF; Cai XJ
World J Gastroenterol; 2020 Feb; 26(8):789-803. PubMed ID: 32148377
[TBL] [Abstract][Full Text] [Related]
37. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract][Full Text] [Related]
38. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
Akce M; El-Rayes BF; Wajapeyee N
Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Pinter M; Scheiner B; Pinato DJ
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):760-770. PubMed ID: 37327807
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]